New York State Teachers Retirement System Sells 8,465 Shares of Boston Scientific Corporation $BSX

New York State Teachers Retirement System decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,217,151 shares of the medical equipment provider’s stock after selling 8,465 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Boston Scientific worth $118,830,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. GAMMA Investing LLC raised its holdings in shares of Boston Scientific by 15.4% during the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the last quarter. State Street Corp grew its position in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Synergy Asset Management LLC raised its stake in Boston Scientific by 3,493.0% during the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in shares of Boston Scientific by 75.3% during the 2nd quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock valued at $17,685,000 after buying an additional 70,753 shares during the period. Finally, MRA Advisory Group purchased a new position in shares of Boston Scientific in the 2nd quarter worth $273,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 93,095 shares of company stock valued at $9,305,450. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $97.68 on Friday. The firm has a market capitalization of $144.80 billion, a price-to-earnings ratio of 52.23, a PEG ratio of 1.73 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The business has a 50 day simple moving average of $97.58 and a 200-day simple moving average of $100.76. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on BSX shares. UBS Group restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday. Finally, Barclays raised their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $125.21.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.